Dabrafenib plus trametinib: potential new therapy for BRAF-mutant NSCLC

Access to the full content of this site is available only to registered healthcare professionals. Register to read more
  • Takeaway

    • Dabrafenib combined with trametinib could be a new treatment for patients with BRAFV600E-mutant NSCLC.

    Study design

    • Phase 2 multicenter, international and non-randomized trial that enrolled 59 patients with pretreated metastatic stage IV BRAFV600E -mutant NSCLC who had progressed af...